More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

Data Submission & Further Communication Request with US FDA

Feb 14, 2018 at 11:18 PM EST · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Feb 14, 2018 at 11:18 PM EST

On 6ix: 6ix.com/news/data-submission-and-further-communication-request-with-us-fda

Recce Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Recce Pharmaceuticals Ltd. on 6ix

Story so far

  • US FDA Grants Qualified Infectious Disease Product DesignatiNov 16, 2017
  • Recce Confirms Pre-IND Data Submission to US FDASep 7, 2017

Earlier from Recce Pharmaceuticals

  • AusIndustry Awards Recce Financial SupportJan 14, 2018
  • US FDA Grants Qualified Infectious Disease Product DesignatiNov 15, 2017
  • Appendix 4C - quarterlyOct 31, 2017
  • Recce Launches Share Purchase PlanSep 27, 2017
  • Response to ASX Price QuerySep 18, 2017

Later from Recce Pharmaceuticals

  • Recce Half Yearly Report and Appendix 4DFeb 28, 2018
  • Additional AU$861,590 R&D Tax Incentive Rebate ReceivedApr 22, 2018
  • Update on meeting with US FDAJun 5, 2018
  • Update on Progress of Broad Spectrum Antibiotic RECCE 327Jul 18, 2018
  • Key Australian Patent for Recces Broad-Spectrum AntibioticsJul 31, 2018
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer